Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon s Revenues, Losses Up in Q4

NEW YORK, Feb. 19 (GenomeWeb News) - Lexicon Genetics today reported increased revenues, losses, and R&D expenses for the fourth quarter of 2003.

 

Revenues for the quarter were $13.7 million, up from $10.1 million during the same period a year ago. Lexicon attributed this increase primarily to a milestone payment from Genentech.

 

The company spent $20.3 million on R&D last quarter, up from $19.2 million during the same quarter in 2002.

 

Lexicon's net loss increased to $14.9 million, or $.24 per share, from $13.9 million, or $.26 per share, during the year-ago period.

 

As of Dec. 31, Lexicon had $161 million in cash and investments, including $57.5 million in restricted cash and investments.

 

Click here for the full earnings report.

 

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.